Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens

Nucleophosmin-1 mutations (NPM1(+)) occur in ∼30% of acute myeloid leukemia (AML) patients. Although typically associated with favorable prognosis, the beneficial impact of NPM1(+) decreases with increasing age in patients treated with standard intensive chemotherapy (IC) or hypomethylating agents (...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Lachowiez, Curtis A., Loghavi, Sanam, Kadia, Tapan M., Daver, Naval, Borthakur, Gautam, Pemmaraju, Naveen, Naqvi, Kiran, Alvarado, Yesid, Yilmaz, Musa, Short, Nicholas, Ohanian, Maro, Pierce, Sherry R., Patel, Keyur P., Qiao, Wei, Ning, Jing, Sasaki, Koji, Takahashi, Koichi, Jabbour, Elias, Andreeff, Michael, Ravandi, Farhad, Kantarjian, Hagop M., Konopleva, Marina, DiNardo, Courtney D.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2020
Assuntos:
Myeloid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7160266/
https://ncbi.nlm.nih.gov/pubmed/32251497
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001267
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados